LeMaitre Vascular (NASDAQ:LMAT) Rating Increased to Buy at Wall Street Zen

LeMaitre Vascular (NASDAQ:LMAT) was upgraded by equities researchers at Wall Street Zen from a “hold” rating to a “buy” rating in a report released on Saturday.

LMAT has been the subject of a number of other research reports. Barrington Research reiterated an “outperform” rating and set a $95.00 price target on shares of LeMaitre Vascular in a research report on Friday. Weiss Ratings reissued a “buy (b-)” rating on shares of LeMaitre Vascular in a research note on Monday, December 29th. Roth Mkm reaffirmed a “buy” rating and issued a $108.00 price target on shares of LeMaitre Vascular in a research note on Wednesday, November 5th. Wells Fargo & Company decreased their price objective on shares of LeMaitre Vascular from $97.00 to $93.00 and set an “equal weight” rating for the company in a report on Friday, November 7th. Finally, Zacks Research cut LeMaitre Vascular from a “strong-buy” rating to a “hold” rating in a report on Thursday, January 1st. Four analysts have rated the stock with a Buy rating and four have issued a Hold rating to the stock. Based on data from MarketBeat, LeMaitre Vascular presently has a consensus rating of “Moderate Buy” and an average target price of $100.20.

LeMaitre Vascular Price Performance

Shares of NASDAQ:LMAT opened at $92.94 on Friday. The firm’s 50 day moving average is $85.54 and its two-hundred day moving average is $88.14. LeMaitre Vascular has a 52 week low of $71.42 and a 52 week high of $105.55. The firm has a market capitalization of $2.11 billion, a P/E ratio of 40.06, a PEG ratio of 2.04 and a beta of 0.72. The company has a current ratio of 13.58, a quick ratio of 11.45 and a debt-to-equity ratio of 0.44.

Hedge Funds Weigh In On LeMaitre Vascular

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Vanguard Group Inc. raised its stake in shares of LeMaitre Vascular by 1.4% in the 4th quarter. Vanguard Group Inc. now owns 1,622,033 shares of the medical instruments supplier’s stock valued at $131,547,000 after acquiring an additional 21,946 shares in the last quarter. First Trust Advisors LP lifted its position in shares of LeMaitre Vascular by 13.4% in the 4th quarter. First Trust Advisors LP now owns 940,140 shares of the medical instruments supplier’s stock worth $76,245,000 after acquiring an additional 111,193 shares during the period. Geneva Capital Management LLC lifted its position in LeMaitre Vascular by 6.0% in the second quarter. Geneva Capital Management LLC now owns 915,238 shares of the medical instruments supplier’s stock worth $76,010,000 after purchasing an additional 51,489 shares during the period. State Street Corp lifted its holdings in shares of LeMaitre Vascular by 0.8% during the 4th quarter. State Street Corp now owns 806,993 shares of the medical instruments supplier’s stock worth $65,447,000 after acquiring an additional 6,130 shares during the period. Finally, Congress Asset Management Co. increased its stake in LeMaitre Vascular by 5.8% in the fourth quarter. Congress Asset Management Co. now owns 732,331 shares of the medical instruments supplier’s stock valued at $59,392,000 after acquiring an additional 40,065 shares during the period. Institutional investors own 84.64% of the company’s stock.

About LeMaitre Vascular

LeMaitre Vascular, Inc is a specialty medical device company focused on the development, manufacture and marketing of products for the treatment of peripheral vascular disease. Headquartered in Burlington, Massachusetts, the company’s offerings include a broad portfolio of vascular surgical instruments, grafts, patches, catheters and embolic protection devices. LeMaitre’s product lines address key areas such as arterial reconstruction, endovascular repair and vascular access, serving the needs of cardiovascular surgeons and interventional specialists.

Founded in 1983 by George D.